<DOC>
	<DOC>NCT00354796</DOC>
	<brief_summary>We hypothesize that reduced dose of enoxaparin in elderly patients will result in reduced proportion of patients with therapeutic anti Xa activity and reduced clinical efficacy.</brief_summary>
	<brief_title>The Effect of Reduced Dose of Enoxaparin on the Outcomes of Treatment With Enoxaparin</brief_title>
	<detailed_description>Patients treated with enoxaparin will be followed, sociodemographic , clinical and laboratory data will be collected. Clinical efficacy as well as adverse events will be monitored.</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Thrombophilia</mesh_term>
	<criteria>treatment with enoxaparin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>bleeding</keyword>
	<keyword>anticoagulation</keyword>
	<keyword>LMWH</keyword>
	<keyword>Enoxaparin</keyword>
</DOC>